Sundar Shyam, Chakravarty Jaya
Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005, India.
J Glob Infect Dis. 2010 May;2(2):159-66. doi: 10.4103/0974-777X.62886.
Liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the Mediterranean region and the preferred drug for HIV/VL co-infection. Although there is a regional variation in the susceptibility of the parasite a total dose of 20 mg/kg is effective in immunocompetent patients. Randomized clinical trials of liposomal amphotericin B in the treatment and secondary prophylaxis of HIV-VL coinfected patients is urgently needed to optimize treatment in this subset. With the availability of Liposomal amphotericin B at a preferential pricing in the endemic areas, short course combination therapy can become a viable alternative.
脂质体两性霉素B已越来越频繁地用于治疗内脏利什曼病（VL）。它是地中海地区免疫功能正常患者的首选治疗药物，也是HIV/VL合并感染的首选药物。尽管寄生虫的易感性存在区域差异，但20mg/kg的总剂量对免疫功能正常的患者有效。迫切需要对脂质体两性霉素B治疗HIV-VL合并感染患者及二级预防进行随机临床试验，以优化该亚组的治疗。随着脂质体两性霉素B在流行地区以优惠价格供应，短程联合治疗可能成为一种可行的替代方案。
